MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
MYRIAD GENETICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$4.21+0.23 (+5.78%)
Close on Oct 19, 2026
- Market cap
- $399.11M
- P/E (TTM)
- –
- Dividend yield
- –
MYRIAD GENETICS INC revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cancer Care Continuum | $114.10M | $120.20M | – | – | $127.70M | $115.60M | – | – | – | – | – | – | 59.8% | -10.6% |
| Prenatal Health | $39.80M | $41.90M | – | – | $47.60M | $49.30M | – | – | – | – | – | – | 20.9% | -16.4% |
| Mental Health | $36.80M | $38.30M | – | – | $37.80M | $31.00M | – | – | – | – | – | – | 19.3% | -2.6% |
| Autoimmune | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
| Pharmacogenomics | – | – | – | $38.70M | $37.80M | $31.00M | $40.60M | $47.70M | $43.00M | $38.90M | $35.60M | $35.70M | – | – |
| Prenatal | – | – | – | $44.50M | $47.60M | $49.30M | – | $43.50M | $44.40M | $44.30M | $40.00M | $39.50M | – | – |
| Tumor Profiling | – | – | $31.50M | $29.50M | $31.40M | $29.30M | $30.70M | $31.60M | $32.60M | $30.90M | $32.10M | $30.20M | – | – |
| Hereditary Cancer | – | – | – | $93.00M | $96.30M | $86.30M | – | $90.50M | $91.50M | $88.10M | $88.90M | $86.50M | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $177.50M | $187.00M | $196.50M | $191.70M | $198.20M | $181.60M | $195.50M | $196.00M | $194.80M | $183.20M | $176.30M | $172.20M | 93.1% | -10.4% |
| RoW | $13.20M | $13.40M | $13.30M | $14.00M | $14.90M | $14.30M | $15.10M | $17.30M | $16.70M | $19.00M | $20.30M | $19.70M | 6.9% | -11.4% |
From the segment and revenue-disaggregation notes of Myriad Genetics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.